Cover Image

Sarilumab‐induced cutaneous adverse event

Saved in:

Bibliographic Details
Main Authors:	Sayaka Sato (Author), Yu Sawada (Author), Motonobu Nakamura (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Macular‐type cutaneous adverse reaction due to atezolizumab and pembrolizumab
by: Hitomi Sugino, et al.
Published: (2022)

Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine
by: Hikaru Nanamori, et al.
Published: (2022)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
by: Raimondo MG, et al.
Published: (2017)

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations
by: Andrea Marino, et al.
Published: (2022)

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
by: Pelechas E, et al.
Published: (2019)

A subcutaneous abscess following anti‐programmed cell death 1/programmed death‐ligand 1 antibody treatment for lung cancer
by: Hitomi Sugino, et al.
Published: (2022)

Acneiform eruption during peficitinib treatment
by: Reiko Hara, et al.
Published: (2022)

Vemurafenib and cutaneous adverse events - report of five cases
by: Giselle de Barros Silva, et al.
Published: (2015)

Cutaneous Adverse Events After COVID-19 Vaccination
by: Weschawalit S, et al.
Published: (2023)

Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts
by: Annett Klinder, et al.
Published: (2022)

Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report
by: Aya Tanaka, et al.
Published: (2019)

Analysis of fall-related adverse events among older adults using the Japanese Adverse Drug Event Report (JADER) database
by: Haruna Hatahira, et al.
Published: (2018)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
by: Zoe Apalla, et al.
Published: (2021)

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis
by: Pavel Kovalenko, et al.
Published: (2020)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies
by: Ferrufino CP, et al.
Published: (2018)

Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
by: Rita Pimenta, et al.
Published: (2021)

Causes of Drug-Induced Severe Cutaneous Adverse Reaction Epidermal Necrolysis (EN): An Analysis Using FDA Adverse Event Reporting System (FAERS) Database
by: Fei W, et al.
Published: (2023)

In Silico Approach to Predict Severe Cutaneous Adverse Reactions Using the Japanese Adverse Drug Event Report Database
by: Kaori Ambe, et al.
Published: (2021)

Adverse cutaneous reactions induced by exposure to woods
by: Dorota Chomiczewska-Skóra
Published: (2013)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
by: Ferrufino CP, et al.
Published: (2019)

Characterization of cutaneous adverse events to enfortumab vedotin: A retrospective case-control study
by: Ahmad Shahin, BS, et al.
Published: (2023)

Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
by: K. Chanprapaph, et al.
Published: (2014)

Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis
by: Lukas Kraehenbuehl, et al.
Published: (2023)

Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events
by: Stephanie L. Gu, et al.
Published: (2023)

Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient
by: Fournier M, et al.
Published: (2019)

Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events
by: Yoo Jung Kim, et al.
Published: (2020)

Identification of cutaneous immune-related adverse events by International Classification of Diseases codes and medication administration
by: Wenxin Chen, BS, et al.
Published: (2022)

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
by: Paul C. Macklis, et al.
Published: (2020)

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events
by: Stephanie L. Gu, et al.
Published: (2023)

Analyses of non-benzodiazepine-induced adverse events and prognosis in elderly patients based on the Japanese adverse drug event report database
by: Yoshihiro Noguchi, et al.
Published: (2018)

Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event
by: Ana Filipe Monteiro, et al.
Published: (2018)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023)

Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
by: William Queiroz Guimarães Wiegandt Ceglio, et al.
Published: (2022)

Analysis of Drug-Induced Gastrointestinal Obstruction and Perforation Using the Japanese Adverse Drug Event Report Database
by: Riko Satake, et al.
Published: (2021)

Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database
by: Yanjing Zhang, et al.
Published: (2024)

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
by: Ming-Tao Wen, et al.
Published: (2024)

Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy
by: Prasanna Duraisamy, et al.
Published: (2023)

Online Patient Attitudes Toward Cutaneous Immune-Related Adverse Events Attributed to Nivolumab and Pembrolizumab: Sentiment Analysis
by: Camille M Powers, et al.
Published: (2024)

Dapagliflozin-Induced Cutaneous Vasculitis, a Hitherto Unreported Adverse Effect
by: Surjyamukhi Bhattacharyya, et al.
Published: (2024)

The pharmacogenomics of carbamazepine-induced cutaneous adverse drug reaction in the South of Vietnam
by: Ai-Hoc Nguyen, et al.
Published: (2023)